On Friday, SBA Communications Corporation (NASDAQ:SBAC)’s shares inclined 2.12% to $120.72.
SBA Communications Corporation (SBAC) declared that its Board of Directors has authorized a new $1.0 billion stock repurchase plan. This new plan authorizes the Company to purchase from time to time the Company’s outstanding common stock through open market repurchases in compliance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended, and/or in privately negotiated transactions at administration’s discretion based on market and business conditions, applicable legal requirements and other factors. Shares purchased will be stepped down. The new plan has no time deadline and will continue until otherwise modified or terminated by the Company’s Board of Directors at any time in the Company’s sole discretion. The new plan is not predictable to result in changes to the Company’s net debt/annualized adjusted EBITDA leverage level targets. The Company also declared the completion of the Company’s prior $300 million stock repurchase plan, repurchasing in May, 2015 the final $150 million of common stock authorized under the plan. The Company repurchased 1.305 million shares, or just over one percent of the shares presently outstanding, at an average price per share of $114.96.
SBA Communications Corporation owns and operates wireless communications tower structures, rooftops, and other structures that support antennas used for wireless communications in the United States and its territories, Canada, Central America, and Brazil. The company operates through two segments, Site Leasing and Site Development.
Hutchinson Technology Incorporated (NASDAQ:HTCH)’s shares gained 25.52% to $1.82.
Hutchinson Technology Incorporated (HTCH) declared that it anticipates to start shipping prototypes of a new Shape Memory Alloy Optical Image Stabilization (SMA OIS) actuator to tier 1 camera module manufacturers in early August. The new Gemini product was designed in response to customer requests for reduced OIS camera thickness. Gemini reduces SMA OIS actuator thickness by more than 70%, to enable the world’s slimmest OIS smartphone cameras.
Gemini also improves handshake suppression, resulting in clearer photos in low light conditions and more stabilized videos. The unique properties of shape memory alloy wire enable a more compact, higher force, and a more rugged actuator than industry standard voice coil motor designs.
Hutchinson Technology Incorporated researches, designs, develops, manufactures, and supplies suspension assemblies for hard disk drives in Thailand, Hong Kong, the Philippines, Malaysia, the United States, and internationally. The company’s suspension assemblies are components in computers, and various consumer electronics and enterprise storage products.
At the end of Friday’s trade, BankUnited (NYSE:BKU)‘s shares surged 0.72% to $36.52.
BankUnited, Inc. (BKU) declared financial results for the quarter ended June 30, 2015.
For the quarter ended June 30, 2015, the Company stated net income of $46.6 million, or $0.43 per diluted share, contrast to $48.5 million, or $0.46 per diluted share, for the quarter ended June 30, 2014.
For the six months ended June 30, 2015, the Company stated net income of $93.1 million, or $0.87 per diluted share. The Company stated net income of $103.8 million, or $0.99 per diluted share, for the six months ended June 30, 2014.
Loans and Leases
Loans, counting premiums, discounts and deferred fees and costs, raised to $14.3 billion at June 30, 2015 from $12.4 billion at December 31, 2014. New loans grew to $13.3 billion while loans attained in the FSB acquisition declined to $993 million at June 30, 2015.
For the quarter ended June 30, 2015, new commercial loans, counting commercial real estate loans, commercial and industrial loans, and loans and leases originated by our commercial finance auxiliaries, grew $974 million to $10.5 billion. New residential loans grew by $185 million to $2.8 billion during the second quarter of 2015.
Fernandez is active in the community, serving on the boards of the Coral Gables Chamber of Commerce, Greater Miami Chamber of Commerce and the Actors’ Playhouse Miracle Theatre. He is an advisory board member for the City of Miami Parks and Recreation Department and is chair of Read2Succeed. He serves as vice president of the Delutri Foundation.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), ended its Friday’s trading session with 4.88% gain, and closed at $17.19.
Amicus Therapeutics, Inc. (FOLD) has been added to the U.S. broad-market Russell 3000(R) and small-cap Russell 2000(R) Indexes. The Company joined the indexes at the close of market on Friday, June 26, 2015, when Russell Investments reconstituted its U.S. and global equity indexes.
Annual reconstitution of Russell’s U.S. indexes captures and ranks the 4,000 largest U.S. stocks as of the end of May by total market capitalization. The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies representing about 98% of the investable U.S. equity market. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000 Index in addition to the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs comprise next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has accomplished two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson’s disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
